None listed
Conditions
Brief summary
This study looks at which types of exercise are most useful in reducing the side effects of hormonal therapy for prostate cancer. Who is it for? You can join this study if you are a man being treated for prostate cancer with androgen deprivation therapy (ADT) to reduce your level of male hormones. Trial details Participants will be divided into three groups. One group will undertake resistance/impact loading exercise. Sessions are 60 minutes each, twice weekly over 12 months. The second group will undertake resistance/cardiovascular exercise. Sessions are 60 minutes each, twice weekly over 6 months. The third group will be provided with a printed booklet with information about exercise for the initial 6-month period, and in the second 6-month period undertake twice weekly cycling exercise sessions. Participants in this group will be also offered a 3-month resistance exercise program following the completion of the second 6-month period. The study will measure cardio-respiratory capacity (maximum oxygen capacity), bone mineral density, blood pressure and artery stiffness, muscle function and other indicators of well-being before, during and immediately after the program. The use of androgen deprivation therapy (ADT) is accompanied by a number of side effects. This study will investigate the effects of exercise on reversing musculoskeletal and cardiovascular related side effects.
Interventions
Resistance/impact loading exercise group (1): progressive supervised resistance (e.g. upper and lower body resistance based exercises using weight machines) and impact loading exercises (e.g. skipping, bounding and drop jumping) twice weekly 60 minutes sessions during 12 months. Resistance/cardiovascular exercise group (2): progressive supervised resistance (e.g. upper and lower body resistance based exercises using weight machines) and aerobic exercises (e.g. walking and cycling) twice weekly 60 minutes sessions during 6 months.
Sponsors
Study design
Eligibility
Inclusion criteria
Prostate cancer patients on androgen suppression (for>2 month) and who are anticipated to remain hypogonadal for the duration of the study (12 months).
Exclusion criteria
(1) metastatic bone disease, established osteoporosis or taking medications known to affect bone metabolism, such as bisphosphonates; (2) presence of musculoskeletal, neurological or cardiovascular disorder that could inhibit them from exercising (will required a GP consent); (3) participated in regular (e.g. 2 to 3 times per week) resistance training in the previous 3 months.